Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients. (1st July 2021)

• Record Type: Journal Article
• Authors: Claassens, Daniel M.F.; Gimbel, Marieke E.; Bergmeijer, Thomas O.; Vos, Gerrit J.A.; Hermanides, Renicus S.; van der Harst, Pim; Barbato, Emanuele; Morisco, Carmine; Tjon Joe Gin, Richard M.; de Vrey, Evelyn A.; Heestermans, Ton A.C.M.; Jukema, J. Wouter; von Birgelen, Clemens; Waalewijn, Reinier A.; Hofma, Sjoerd H.; den Hartog, Frank R.; Voskuil, Michiel; van't Hof, Arnoud W.J.; Asselbergs, Folkert W.; Mosterd, A.; Herrman, Jean-Paul R.; Dewilde, Willem; Mahmoodi, Bakhtawar K.; Deneer, Vera H.M.; ten Berg, Jurriën M.
• Is Part Of: International journal of cardiology. Volume 334(2021)
• Page Start: 10
• Page End: 17
• Publication Date: 2021-07-01
• Subjects: Myocardial infarction -- CYP2C19 -- Pharmacogenetics -- P2Y12 -- Older -- Genotyping; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2021.04.029
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Background: Patients with acute coronary syndrome (ACS) who are carrying CYP2C19 loss-of-function alleles derive less benefit from clopidogrel treatment. Despite this, in elderly patients, clopidogrel might be preferred over more potent P2Y12 inhibitors due to a lower bleeding risk. Whether CYP2C19 genotype-guided antiplatelet treatment in the elderly could be of benefit has not been studied specifically. Methods: Patients aged 70 years and older with known CYP2C19*2 and *3 genotype were identified from the POPular Genetics and POPular Age trials. Noncarriers of loss-of-function alleles treated with clopidogrel were compared to patients, irrespective of CYP2C19 genotype, treated with ticagrelor and to clopidogrel treated carriers of loss-of-function alleles. We assessed net clinical benefit (all-cause death, myocardial infarction, stroke and Platelet Inhibition and Patient Outcomes (PLATO) major bleeding), atherothrombotic outcomes (cardiovascular death, myocardial infarction, stroke) and bleeding outcomes (PLATO major and minor bleeding). Results: A total of 991 patients were assessed. There was no significant difference in net clinical benefit (17.2% vs. 15.1%, adjusted hazard ratio (adjHR) 1.05, 95% confidence interval (CI) 0.77–1.44), atherothrombotic outcomes (9.7% vs. 9.2%, adjHR 1.00, 95%CI 0.66–1.50), and bleeding outcomes (17.7% vs. 19.8%, adjHR 0.80, 95%CI 0.62–1.12) between clopidogrel in noncarriers of loss-of-function alleles and ticagrelor respectively. Conclusion: In ACS patients aged 70 years and older, there was no significant difference in net clinical benefit and atherothrombotic outcomes between noncarriers of a loss-of-function allele treated with clopidogrel and patients treated with ticagrelor. The bleeding rate was numerically; though not statistically significant, lower in patients using clopidogrel. Highlights: This subgroup analysis included acute coronary syndrome patients aged 70 and older. Clopidogrel in noncarriers of CYP2C19 LoF was compared to ticagrelor. In this small subgroup, no differences in bleeding and ischemic outcomes were found. Overall, results were comparable to the POPular Genetics main trial results.